• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by XOMA Royalty Corporation

    7/20/26 4:35:01 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email
    S-8 POS 1 d119146ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on July 20, 2026

    Registration No. 333-108306

    Registration No. 333-151416

    Registration No. 333-171429

    Registration No. 333-174730

    Registration No. 333-181849

    Registration No. 333-198719

    Registration No. 333-204367

    Registration No. 333-212238

    Registration No. 333-218378

    Registration No. 333-232398

    Registration No. 333-265248

    Registration No. 333-269459

    Registration No. 333-272054

    Registration No. 333-294409

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8 REGISTRATION STATEMENT NO. 333-108306

    FORM S-8 REGISTRATION STATEMENT NO. 333-151416

    FORM S-8 REGISTRATION STATEMENT NO. 333-171429

    FORM S-8 REGISTRATION STATEMENT NO. 333-174730

    FORM S-8 REGISTRATION STATEMENT NO. 333-181849

    FORM S-8 REGISTRATION STATEMENT NO. 333-198719

    FORM S-8 REGISTRATION STATEMENT NO. 333-204367

    FORM S-8 REGISTRATION STATEMENT NO. 333-212238

    FORM S-8 REGISTRATION STATEMENT NO. 333-218378

    FORM S-8 REGISTRATION STATEMENT NO. 333-232398

    FORM S-8 REGISTRATION STATEMENT NO. 333-265248

    FORM S-8 REGISTRATION STATEMENT NO. 333-269459

    FORM S-8 REGISTRATION STATEMENT NO. 333-272054

    FORM S-8 REGISTRATION STATEMENT NO. 333-294409

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    XOMA ROYALTY LLC

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   52-2154066

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    c/o XOMA Royalty LLC

    2200 Powell Street, Suite 310

    Emeryville, CA 94608

    (Address of Principal Executive Offices, Zip Code)

    XOMA Ltd. 1981 Share Option Plan

    XOMA Ltd. 1992 Directors Share Option Plan

    XOMA Corporation 1998 Employee Stock Purchase Plan

    XOMA Ltd. 2002 Directors Share Option Plan

    XOMA Ltd. 2007 CEO Share Option Plan

    XOMA Royalty Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan

    XOMA Corporation 2015 Employee Stock Purchase Plan

    XOMA Ltd. Restricted Share Plan

    XOMA Ltd. Management Incentive Plan

    c/o XOMA Royalty LLC

    2200 Powell Street, Suite 310

    Emeryville, CA 94608

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    These post-effective amendments (these “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”) filed with the Securities and Exchange Commission (the “SEC”) by XOMA Royalty Corporation or its predecessors, prior to giving effect to its conversion to XOMA Royalty LLC, a Delaware limited liability company on July 14, 2026 (the “Registrant”):

     

      •  

    Registration Statement No.  333-108306, filed with the SEC on August 28, 2003, pertaining to the registration of (i) 10,250,000 shares of common stock of the Registrant, $0.0005 par value per share (the “Common Stock”) issuable under the XOMA Ltd. 1981 Share Option Plan (the “1981 Share Option Plan”), the XOMA Ltd. Restricted Share Plan (“Restricted Share Plan”), and the XOMA Ltd. Management Incentive Plan (the “MIP”), (ii) 300,000 shares of Common Stock issuable under the XOMA Ltd. 1992 Directors Share Option Plan (the “1992 Directors Share Option Plan”), (iii) 15,000 shares of Common Stock issuable under the XOMA Ltd. 2002 Directors Share Option Plan (the “2002 Directors Share Option Plan”) and (iv) 1,000,000 shares of Common Stock issuable under the Xoma Corporation 1998 Employee Stock Purchase Plan (the “1998 ESPP”).

     

      •  

    Registration Statement No.  333-151416, filed with the SEC on June 4, 2008, pertaining to the registration of (i) 14,450,000 shares of Common Stock issuable under the 1981 Share Option Plan and Restricted Share Plan, (ii) 1,100,000 shares of Common Stock issuable under the XOMA Ltd. 2007 CEO Share Option Plan (the “2007 CEO Share Option Plan”) and (iii) 1,050,000 shares of Common Stock issuable under the 1992 Directors Share Option Plan.

     

      •  

    Registration Statement No.  333-171429, filed with the SEC on December 27, 2010, pertaining to the registration of (i) 586,667 shares of Common Stock (par value $.0075 per share) issuable under the XOMA Ltd. 2010 Long Term Incentive and Share Award Plan (as amended and restated, the “2010 Plan”), (ii) 780,000 shares of Common Stock (par value $.0075 per share) issuable under the 1981 Share Option Plan and Restricted Share Plan, (iii) 16,667 shares of Common Stock (par value $.0075 per share) issuable under the 1992 Directors Share Option Plan, and (iv) 33,333 shares of Common Stock (par value $.0075 per share) issuable under the 1998 ESPP.

     

      •  

    Registration Statement No.  333-174730, filed with the SEC on June 6, 2011, pertaining to the registration of (i) 5,500,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan, and (ii) 100,000 shares of Common Stock (par value $.0075 per share) issuable under the 1998 ESPP.

     

      •  

    Registration Statement No.  333-181849, filed with the SEC on June 1, 2012, pertaining to the registration of 7,000,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan.

     

      •  

    Registration Statement No.  333-198719, filed with the SEC on September 12, 2014, pertaining to the registration of 5,350,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan.

     

      •  

    Registration Statement No.  333-204367, filed with the SEC on May 21, 2015, pertaining to the registration of 300,000 shares of Common Stock (par value $.0075 per share) issuable under the XOMA Corporation 2015 Employee Stock Purchase Plan (the “2015 ESPP”).

     

      •  

    Registration Statement No.  333-212238, filed with the SEC on June 24, 2016, pertaining to the registration of 3,400,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan.

     

      •  

    Registration Statement No.  333-218378, filed with the SEC on May 31, 2017, pertaining to the registration of (i) 1,470,502 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan, and (ii) 250,000 shares of Common Stock (par value $.0075 per share) issuable under the 2015 ESPP.


      •  

    Registration Statement No.  333-232398, filed with the SEC on June 27, 2019, pertaining to the registration of 450,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan.

     

      •  

    Registration Statement No.  333-265248, filed with the SEC on May 26, 2022, pertaining to the registration of 275,000 shares of Common Stock (par value $.0075 per share) issuable under the 2010 Plan.

     

      •  

    Registration Statement No.  333-269459, filed with the SEC on January 30, 2023, pertaining to the registration of (i) 100,000 shares of Common Stock (par value $.0075 per share) issuable upon the exercise of a non-qualified stock option award with an exercise price of $18.66 granted to Owen Hughes on January 3, 2023, (ii) 75,000 shares of Common Stock (par value $.0075 per share) issuable upon the exercise of a non-qualified stock option award with an exercise price of $30.00 granted to Owen Hughes on January 3, 2023, (iii) 300,000 shares of Common Stock (par value $.0075 per share) issuable upon the exercise of a non-qualified stock option award with an exercise price of $18.66 granted to Bradley Sitko on January 3, 2023, 100,000 shares of Common Stock (par value $.0075 per share) issuable upon the exercise of a non-qualified stock option award with an exercise price of $30.00 granted to Bradley Sitko on January 3, 2023, in each case granted outside of the 2010 Plan and issued pursuant to the “inducement” grant exception under Nasdaq Rule 5635(c)(4).

     

      •  

    Registration Statement No.  333-272054, filed with the SEC on May 18, 2023, pertaining to the registration of 709,000 shares of Common Stock (par value $.0075 per share) issuable pursuant to the 2010 Plan.

     

      •  

    Registration Statement No.  333-294409, filed with the SEC on March 18, 2026, pertaining to the registration of 880,000 shares of Common Stock (par value $.0075 per share) issuable pursuant to the 2010 Plan.

    On July 14, 2026, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 27, 2026, by and among the Registrant, Ligand Pharmaceuticals Incorporated, a Delaware Corporation (“Parent”), Flex Merger Sub, Inc., a Nevada corporation and wholly owned subsidiary of Parent (“Merger Sub”) and XOMA Royalty Holdings Corporation, a Nevada corporation (“HoldCo”), Merger Sub merged with and into HoldCo with HoldCo surviving the Merger as a wholly owned subsidiary of Parent (the “Merger”).

    Prior to giving effect to the Merger, the Registrant effected a restructuring pursuant to which, among other matters, the Registrant converted from a Nevada corporation to a Delaware limited liability company (the “Conversion”). Reference herein to the “Registrant” refers to (i) “XOMA Royalty Corporation” with respect to matters occurring prior to the effectiveness of the Conversion, and (ii) “XOMA Royalty LLC” with respect to matters occurring on and after the effectiveness of the Conversion.

    As a result of the Merger, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, by filing these Post-Effective Amendments, the Registrant hereby removes from registration all securities registered but unsold under the Registration Statements, if any, as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, on the 20th day of July, 2026.

     

    XOMA ROYALTY LLC

    By:

     

    /s/ Owen Hughes

    Name:

     

    Owen Hughes

    Title:

     

    Authorized Person

    Get the next $XOMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on XOMA with a new price target

    Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

    4/29/24 8:01:47 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on XOMA with a new price target

    HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

    10/8/21 6:18:28 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Bvf Partners L P/Il

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/16/26 5:02:46 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Montano Maricel Perea disposed of 42,371 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/14/26 9:45:21 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Limber Joseph M disposed of 9,532 shares, returned 10,000 units of 8.625% Series A Cumulative Perpetual Preferred Stock to the company and returned 20,000 units of Depositary Shares - 8.375% Series B Cumulative Stock to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/14/26 9:45:19 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    SEC Filings

    View All

    SEC Form S-8 POS filed by XOMA Royalty Corporation

    S-8 POS - XOMA Royalty Corp (0000791908) (Filer)

    7/20/26 4:40:10 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by XOMA Royalty Corporation

    S-8 POS - XOMA Royalty Corp (0000791908) (Filer)

    7/20/26 4:36:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by XOMA Royalty Corporation

    S-8 POS - XOMA Royalty Corp (0000791908) (Filer)

    7/20/26 4:35:07 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Its Acquisition by Ligand

    EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the transaction announced on April 27, 2026, Ligand acquired all of the outstanding shares of XOMA Royalty common stock. XOMA Royalty stockholders received $39.00 in cash per share of XOMA Royalty common stock owned. XOMA Royalty stockholders and equity award holders also received one non-transferable Contingent Value Right ("CVR") per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending liti

    7/14/26 9:00:00 AM ET
    $XOMA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

    EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's (i) 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) (the "Series A Preferred Stock") (984,000 shares outstanding, CUSIP No. 98419J305) and (ii) depositary shares representing its 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO) (represented by 1,760,500 Depositary Shares) (the "Series B Preferred Stock", and together with the Series A Preferred Stock, the "Preferred Stock") (CUSIP No. 98419J404). In addition, on July 14

    6/12/26 4:05:00 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

    Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

    4/27/26 7:00:00 AM ET
    $LGND
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

    EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's (i) 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) (the "Series A Preferred Stock") (984,000 shares outstanding, CUSIP No. 98419J305) and (ii) depositary shares representing its 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO) (represented by 1,760,500 Depositary Shares) (the "Series B Preferred Stock", and together with the Series A Preferred Stock, the "Preferred Stock") (CUSIP No. 98419J404). In addition, on July 14

    6/12/26 4:05:00 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

    Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate

    4/27/26 7:00:00 AM ET
    $LGND
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.    Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about April 15, 2026, to r

    3/18/26 4:30:00 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hughes Owen bought $2,505,000 worth of Depositary Shares - 8.375% B Cumulative Stock (100,000 units at $25.05), increasing direct ownership by 5,000% to 102,000 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    12/8/25 4:30:18 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    XOMA Royalty Announces CFO Transition

    EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his position with XOMA Royalty to pursue other professional opportunities.   "Tom's leadership, guidance, and resourcefulness have been invaluable as the Company transitioned to and established itself as a royalty aggregator," stated Owen Hughes, XOMA Royalty's Chief Executive Officer.  "On behalf of the Board of Directors and my XOMA Royalty colleagues, I would like to thank Tom for his nearly two decades of service to the Company, his unwavering dedication, and the strong financial foundation h

    1/12/26 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

    Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

    5/9/24 7:30:00 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actym Therapeutics Appoints Thomas Smart as CEO

    BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

    4/24/24 9:00:00 AM ET
    $ANAB
    $PGEN
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

    SC 13G/A - XOMA Corp (0000791908) (Subject)

    2/9/24 10:05:21 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

    SC 13D/A - XOMA Corp (0000791908) (Subject)

    1/16/24 5:22:40 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

    SC 13G/A - XOMA Corp (0000791908) (Subject)

    2/9/23 12:46:50 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care